NeuroMab™ Anti-Alpha Synuclein BBB Shuttle Antibody (NRZP-1022-ZP2541)

Product Overview

Description

Brain uptake of therapeutic antibodies is severely limited by their size. To achieve enhanced BBB crossing, Creative Biolabs developed a BBB shuttle antibody platform by utilizing the endogenous macromolecule transportation pathway, known as receptor-mediated transcytosis (RMT). The engineered antibody-based carrier is believed to significantly to increase the macromolecule brain entry to combat CNS diseases.
Notes: The BBB antibody is made-to order and available in a customized format. Please don't hesitate contact us for more details.

Species Reactivity

Human

Clonality

Monoclonal

Host Species

Human

Applications

WB; ELISA; IHC; In Vitro; In Vivo

Product Properties

Storage

Store at -20°C. Do not aliquot the antibody.

Research Use Only

For research use only

Target

Alpha Synuclein

Official Name

SNCA

Full Name

Alpha-synuclein

Alternative Names

SNCA; NACP; PARK1; PARK4; PD1; synuclein alpha

Product Pictures

ELISA

Fig.1 Recombinant human NI-202.21D11 selectively binds human α-synuclein over β-, γ-synuclein and murine α-synuclein in a direct ELISA.

Recombinant NI-202.21D11 selectively binds α-synuclein whereas pan-synuclein antibody binds to all three synuclein proteins confirming equal coating of recombinant proteins

ELISA

Fig.2 Recombinant human NI-202.21D11 selectively binds human α-synuclein over β-, γ-synuclein and murine α-synuclein in a direct ELISA.

Recombinant NI-202.21D11 is selective for human vs murine α-synuclein. On the other hand NI-202.12F4 binds to both human and murine α-synuclein in a direct ELISA.

ELISA

Fig.3 Recombinant NI-202.21D11 preferentially binds to high density coated α-synuclein.

Recombinant human α-synuclein was coated onto ELISA plates at indicated concentrations and probed with various concentrations of NI-202.21D11 by direct ELISA (□ 20 μg/ml; ▴ 5 μg/ml; ♦ 1 μg/ml; ▪0.25 μg/ml; ▾0.1 μg/ml). The half maximal effective concentration (EC50) indicating the potency of the antibody was determined for each coating concentration.

Fig.4 Epitope mapping revealed a C-terminal binding epitope within human α-synuclein (aa 117-123 of SEQ ID NO:1) for NI-202.21D11.

Pepscan analysis showed binding of NI-202.21D11 to overlapping peptides B08 (aa 109-123 of SEQ ID NO:1), B09 (aa 113-127 of SEQ ID NO:1) and B10 (aa 117-131 of SEQ ID NO:1) of human α-synuclein suggesting that the minimal sequence required for NI-202.21D11 binding is PVDPDNE (aa 117-123 of SEQ ID NO:1) within human α-synuclein.

Publications